CureApp, Inc.

CureApp, Inc., founded in 2014 by two physicians, is a leading "digital therapeutics" startup in the vertical of "medical apps exhibiting therapeutic effects against diseases" in the clinical field. We have raised more than 20 million USD funding, and developed a pipeline of digital therapeutic products "CureApp" for diseases including NASH (non-alcoholic steatohepatitis), hypertension and nicotine addiction, which is currently under clinical trial.